MCF Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $981K | Buy |
16,168
+282
| +2% | +$16.4K | 0.04% | 171 |
|
|
2025
Q4 | $857K | Buy |
15,886
+8,406
| +112% | +$404K | 0.05% | 152 |
|
|
2025
Q3 | $337K | Sell |
7,480
-103
| -1% | -$4.81K | 0.02% | 193 |
|
|
2025
Q2 | $351K | Buy |
7,583
+474
| +7% | +$23.3K | 0.02% | 177 |
|
|
2025
Q1 | $434K | Sell |
7,109
-26
| -0.4% | -$1.52K | 0.03% | 159 |
|
|
2024
Q4 | $404K | Hold |
7,135
| – | – | 0.03% | 165 |
|
|
2024
Q3 | $369K | Buy |
7,135
+26
| +0.4% | +$1.22K | 0.03% | 172 |
|
|
2024
Q2 | $295K | Sell |
7,109
-278
| -4% | -$12.4K | 0.02% | 185 |
|
|
2024
Q1 | $401K | Sell |
7,387
-170
| -2% | -$8.66K | 0.03% | 155 |
|
|
2023
Q4 | $388K | Buy |
7,557
+27
| +0.4% | +$1.42K | 0.03% | 155 |
|
|
2023
Q3 | $437K | Buy |
7,530
+133
| +2% | +$8.15K | 0.04% | 135 |
|
|
2023
Q2 | $473K | Hold |
7,397
| – | – | 0.04% | 128 |
|
|
2023
Q1 | $513K | Hold |
7,397
| – | – | 0.05% | 124 |
|
|
2022
Q4 | $532K | Hold |
7,397
| – | – | 0.05% | 110 |
|
|
2022
Q3 | $526K | Sell |
7,397
-22
| -0.3% | -$1.6K | 0.06% | 101 |
|
|
2022
Q2 | $573K | Buy |
7,419
+500
| +7% | +$38.1K | 0.06% | 84 |
|
|
2022
Q1 | $505K | Buy |
+6,919
| New | +$465K | 0.05% | 108 |
|
|
2021
Q4 | – | Sell |
-6,985
| Closed | -$413K | – | 122 |
|
|
2021
Q3 | $413K | Buy |
6,985
+89
| +1% | +$5.86K | 0.04% | 120 |
|
|
2021
Q2 | $461K | Buy |
6,896
+1,330
| +24% | +$86.7K | 0.05% | 96 |
|
|
2021
Q1 | $351K | Sell |
5,566
-785
| -12% | -$48.8K | 0.04% | 115 |
|
|
2020
Q4 | $394K | Hold |
6,351
| – | – | 0.05% | 89 |
|
|
2020
Q3 | $383K | Buy |
6,351
+118
| +2% | +$7.1K | 0.05% | 88 |
|
|
2020
Q2 | $366K | Hold |
6,233
| – | – | 0.05% | 93 |
|
|
2020
Q1 | $347K | Hold |
6,233
| – | – | 0.06% | 92 |
|
|
2019
Q4 | $400K | Buy |
6,233
+752
| +14% | +$43.1K | 0.06% | 93 |
|
|
2019
Q3 | $278K | Hold |
5,481
| – | – | 0.05% | 123 |
|
|
2019
Q2 | $249K | Hold |
5,481
| – | – | 0.04% | 130 |
|
|
2019
Q1 | $261K | Sell |
5,481
-839
| -13% | -$41.8K | 0.05% | 119 |
|
|
2018
Q4 | $329K | Buy |
6,320
+5
| +0.1% | +$269 | 0.06% | 95 |
|
|
2018
Q3 | $392K | Buy |
6,315
+4
| +0.1% | +$237 | 0.07% | 85 |
|
|
2018
Q2 | $349K | Sell |
6,311
-763
| -11% | -$41.2K | 0.07% | 91 |
|
|
2018
Q1 | $447K | Sell |
7,074
-2,130
| -23% | -$137K | 0.09% | 71 |
|
|
2017
Q4 | $564K | Buy |
9,204
+25
| +0.3% | +$1.56K | 0.1% | 60 |
|
|
2017
Q3 | $585K | Sell |
9,179
-59
| -0.6% | -$3.44K | 0.11% | 57 |
|
|
2017
Q2 | $515K | Buy |
9,238
+827
| +10% | +$45K | 0.1% | 56 |
|
|
2017
Q1 | $457K | Buy |
8,411
+646
| +8% | +$35.4K | 0.1% | 58 |
|
|
2016
Q4 | $454K | Buy |
7,765
+28
| +0.4% | +$1.53K | 0.1% | 57 |
|
|
2016
Q3 | $417K | Sell |
7,737
-4,422
| -36% | -$284K | 0.1% | 62 |
|
|
2016
Q2 | $894K | Buy |
12,159
+3,552
| +41% | +$251K | 0.22% | 38 |
|
|
2016
Q1 | $550K | Sell |
8,607
-1,342
| -13% | -$84.6K | 0.14% | 47 |
|
|
2015
Q4 | $684K | Buy |
9,949
+627
| +7% | +$41.4K | 0.18% | 37 |
|
|
2015
Q3 | $552K | Buy |
9,322
+31
| +0.3% | +$1.97K | 0.14% | 42 |
|
|
2015
Q2 | $618K | Sell |
9,291
-146
| -2% | -$9.62K | 0.16% | 35 |
|
|
2015
Q1 | $609K | Buy |
9,437
+34
| +0.4% | +$2.13K | 0.15% | 35 |
|
|
2014
Q4 | $555K | Sell |
9,403
-480
| -5% | -$27.1K | 0.15% | 40 |
|
|
2014
Q3 | $513K | Buy |
9,883
+133
| +1% | +$6.64K | 0.15% | 47 |
|
|
2014
Q2 | $507K | Sell |
9,750
-9
| -0.1% | -$444 | 0.16% | 44 |
|
|
2014
Q1 | $507K | Buy |
9,759
+44
| +0.5% | +$2.34K | 0.17% | 45 |
|
|
2013
Q4 | $505K | Sell |
9,715
-62
| -0.6% | -$3.16K | 0.18% | 41 |
|
|
2013
Q3 | $508K | Buy |
9,777
+501
| +5% | +$22K | 0.28% | 35 |
|
|
2013
Q2 | $482K | Buy |
+9,276
| New | +$403K | 0.29% | 34 |
|
Other funds holding BMY
VCM
VPM
MCF Advisors's BMY Position: Q1 2026 in Review
MCF Advisors increased its Bristol-Myers Squibb (BMY) stake by 1.8% in Q1 2026, buying an estimated $16.4K and bringing the position to 16,168 shares worth $981K. The position accounts for 0.04% of the portfolio, ranked #171.
MCF Advisors first reported a position in BMY in Q2 2013 and has held it in 51 quarters since. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- MCF Advisors held 16,168 shares of Bristol-Myers Squibb worth $981K as of Q1 2026.
- MCF Advisors bought 282 Bristol-Myers Squibb shares in Q1 2026, an estimated $16.4K.
- Bristol-Myers Squibb made up 0.04% of MCF Advisors's portfolio in Q1 2026, its #171 holding.
- MCF Advisors first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 51 quarters since.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on MCF Advisors's 13F filing for Q1 2026, filed 11 May 2026.